Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
When does Spotify Wrapped come out? The music streamer says 'soon.' - 2Pentagon advances Golden Dome missile defense with new Space Force contracts
- 3Vaccine committee votes to scrap universal hepatitis B shots for newborns despite outcry from children’s health experts
- 4Top 5 Top of the line Books of the Year
- 5Sydney Sweeney is returning in 'The Housemaid's Secret': What to know about 'The Housemaid' sequel
- The Best Portable Applications for Emotional wellness and Prosperity
- Courageous Climbing: Trails and Stuff for Outside Lovers
- Remote Headphones: Upgrade Your Sound Insight
- What is the Significant Tech Expertise to Master Today?
- Blood pressure drug recalled for possible cross-contamination
- 19 Peculiar Films You Shouldn't Watch With Your Mum
- Pedal Power: Divulging Well known Bike Brands for Each Cyclist
- Figure out How to Upgrade Your Gold Speculation Portfolio: Vital Bits of knowledge and Strategies
- Uzbekistan launches €9.46 billion green energy push, covering nation’s power needs
